<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs demonstrated to be effective for gastroesophageal reflux disease in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs demonstrated to be effective for gastroesophageal reflux disease in children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drugs demonstrated to be effective for gastroesophageal reflux disease in children</div><div class="cntnt"><table cellspacing="0"><colgroup width="16%"></colgroup><colgroup span="3" width="28%"></colgroup> <tbody> <tr> <td class="subtitle1">Type of medication</td> <td class="subtitle1">Recommended oral dose</td> <td class="subtitle1">Adverse effects/precautions<sup>*</sup></td> <td class="subtitle1">Useful dose forms for children<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="4">Proton pump inhibitors (PPIs)<sup>Δ◊</sup></td> </tr> <tr> <td class="indent1">Omeprazole</td> <td>Infants 1 to 11 months (daily): <ul class="decimal_heading"> <li>3 to &lt;5 kg – 2.5 mg</li> <li>5 to &lt;10 kg – 5 mg</li> <li>≥ 10 kg – 10 mg</li> </ul> <p class="extra_spacing_top">Children ≥1 year:</p> <ul class="decimal_heading"> <li>1 mg/kg daily, given 30 minutes before meal(s)<sup>§</sup></li> <li>May increase to 1 mg/kg twice daily if needed for symptomatic improvement</li> </ul> <p class="extra_spacing_top">Adults:</p> <ul class="decimal_heading"> <li>20 or 40 mg once daily</li> </ul> </td> <td> <ul> <li>Safety data for long-term use of PPIs in children are in general reassuring<sup>*</sup>.</li> <li><strong>Frequent (2 to 14%) –</strong> Headache, diarrhea, abdominal pain, nausea, rash, constipation.</li> <li><strong>Infrequent or rare –</strong> Increased risk of <em>C. difficile</em> and other enteric infections; increased risk for lower respiratory tract infections in infants (pediatric reports). Malabsorption of magnesium, calcium, and, to a lesser extent, vitamin B12 and iron (adult reports).</li> <li>United States FDA approval is for use in pediatric patients 1 month and older.</li> </ul> </td> <td> <ul> <li>Capsules can be opened and sprinkled on soft food (10, 20, and 40 mg)</li> <li>Flavored oral suspension (2 mg/mL)</li> <li>Granules for oral suspension (2.5 and 10 mg)</li> </ul> </td> </tr> <tr> <td class="indent1">Omeprazole and sodium bicarbonate</td> <td>Similar to omeprazole</td> <td> <ul> <li>Similar to other PPIs<sup>*</sup>.</li> <li>Avoid using in patients on sodium-restricted diets; contains 303 mg (13 mmol) sodium per 20 or 40 mg capsule; 460 mg (20 mmol) sodium per 20 or 40 mg packet.</li> <li>United States FDA approval is for adults 18 years and older.</li> </ul> </td> <td> <ul> <li>Capsules should not be opened (20 and 40 mg capsules)</li> <li>Powder for oral suspension should be dissolved in water only (20 or 40 mg packets)</li> </ul> </td> </tr> <tr> <td class="indent1">Esomeprazole</td> <td>Infants 1 to 11 months (daily): <ul class="decimal_heading"> <li>3 to 5 kg – 2.5 mg</li> <li>5 to 7.5 kg – 5 mg</li> <li>7.5 to 12 kg – 10 mg</li> </ul> <p class="extra_spacing_top">Children 1 to 11 years (daily, given 30 minutes before first meal each day):</p> <ul class="decimal_heading"> <li>Weight &lt;20 kg – 10 mg</li> <li>Weight &gt;20 kg – 10 mg or 20 mg<sup>§</sup></li> </ul> <p class="extra_spacing_top">Children ≥12 years and adults:</p> <ul class="decimal_heading"> <li>20 or 40 mg daily</li> </ul> </td> <td> <ul> <li>Similar to other PPIs<sup>*</sup>.</li> <li>Indication in infants is for erosive esophagitis due to acid-mediated GERD.</li> </ul> </td> <td> <ul> <li>Capsules can be opened and sprinkled on soft food (20 and 40 mg)</li> <li>Granules for oral suspension (2.5, 5, 10, 20, and 40 mg packets</li> <li>Intravenous formulation available<sup>¥</sup></li> </ul> </td> </tr> <tr> <td class="indent1">Lansoprazole</td> <td>Infants and children: <ul class="decimal_heading"> <li>1 mg/kg daily, given 30 minutes before meal(s)<sup>§</sup></li> <li>May increase to 1 mg/kg twice daily, if needed, for symptomatic improvement</li> </ul> <p class="extra_spacing_top">Adults:</p> <ul class="decimal_heading"> <li>15 to 30 mg once daily</li> </ul> </td> <td> <ul> <li>Similar to other PPIs<sup>*</sup>.</li> </ul> </td> <td> <ul> <li>Capsules can be opened and sprinkled on soft food, or given via NG or other enteral tube suspended in apple juice (15 and 30 mg capsules)</li> <li>Flavored oral suspension (3 mg/mL)</li> <li>Orally disintegrating tablets can be dissolved in the mouth or suspended in water and given by oral syringe or NG or other enteral tube (15 and 30 mg tablets)</li> </ul> </td> </tr> <tr> <td class="indent1">Dexlansoprazole</td> <td>Children ≥12 years and adults: <ul class="decimal_heading"> <li>30 mg once daily</li> </ul> </td> <td> <ul> <li>Similar to other PPIs<sup>*</sup>.</li> </ul> </td> <td> <ul> <li>Capsules can be opened and sprinkled on applesauce and consumed immediately or suspended in water and given by oral syringe (30 mg capsules)</li> <li>Orally disintegrating tablets can be dissolved in the mouth or suspended in water and given by oral syringe or NG or other enteral tube (30 mg tablets)</li> </ul> </td> </tr> <tr> <td class="indent1">Pantoprazole</td> <td>Children ≥5 years: <ul class="decimal_heading"> <li>Weight 15 to &lt;40 kg – 20 mg</li> <li>Weight ≥40 kg – 40 mg</li> </ul> <p class="extra_spacing_top">Adults:</p> <ul class="decimal_heading"> <li>40 mg once daily</li> </ul> </td> <td> <ul> <li>Similar to other PPIs<sup>*</sup>.</li> </ul> </td> <td> <ul> <li>Oral tablets should be swallowed whole (20 and 40 mg).</li> <li>Granules for oral suspension (40 mg packets)</li> <li>Intravenous formulation available<sup>¥</sup></li> </ul> </td> </tr> <tr> <td class="indent1">Rabeprazole</td> <td>Children ≥12 years and adults: <ul class="decimal_heading"> <li>20 mg once daily, given 30 minutes before the first meal each day</li> </ul> </td> <td> <ul> <li>Similar to other PPIs<sup>*</sup>.</li> </ul> </td> <td> <ul> <li>Oral tablets should be swallowed whole (20 mg)</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Histamine<sub>2</sub> receptor antagonists (H2RAs)<sup>Δ‡†</sup></td> </tr> <tr> <td class="indent1">Cimetidine</td> <td>Children: <ul class="decimal_heading"> <li>30 to 40 mg/kg per day divided in 4 doses<sup>§</sup></li> </ul> <p class="extra_spacing_top">Adult dose:</p> <ul class="decimal_heading"> <li>400 to 800 mg twice daily</li> </ul> </td> <td> <ul> <li>Safety data for the use of H2RAs in children are in general reassuring. H2RAs produce less profound acid suppression than PPIs, which may be an advantage in some clinical scenarios<sup>*</sup>.</li> <li>Tachyphylaxis (tolerance) commonly develops with chronic use (ie, &gt;6 weeks).</li> <li><strong>Frequent –</strong> Headache, dizziness, diarrhea, abdominal pain, somnolence (adult reports).</li> <li><strong>Infrequent or rare –</strong> CNS disturbance, gynecomastia, idiosyncratic or immune-mediated hypersensitivity including organ toxicity (liver, kidney) and hematologic abnormalities (myelosuppression, thrombocytopenia, neutropenia, anemia, pancytopenia) (mostly adult reports). Rapid intravenous administration has been associated with bradycardia and hypotension. Increased risk of <em>C. difficile</em> and other enteric infections (pediatric and adult reports).</li> <li>Cimetidine is a moderate inhibitor of CYP metabolism and can increase levels of some co-administered medications, such as theophylline, SSRIs, warfarin, and cisapride. For specific interactions, refer to the <a href="https://www.uptodate.com/drug-interactions">drug interactions program</a> included with UpToDate.</li> </ul> </td> <td> <ul> <li>Oral tablets may be crushed (200, 300, 400, and 800 mg)</li> <li>Flavored oral solution (300 mg/5 mL)</li> <li>Intravenous formulation available<sup>¥</sup></li> </ul> </td> </tr> <tr> <td class="indent1">Famotidine</td> <td>Children: <ul class="decimal_heading"> <li>1 mg/kg per day, divided into 2 doses<sup>§</sup></li> </ul> <p class="extra_spacing_top">Adults:</p> <ul class="decimal_heading"> <li>20 mg/dose twice daily</li> </ul> </td> <td> <ul> <li>Similar to cimetidine, except that famotidine <strong>lacks</strong> anti-androgenic activity (gynecomastia) and does <strong>not</strong> inhibit CYP metabolism or alter co-administered drugs metabolized by CYP<sup>*</sup>.</li> </ul> </td> <td> <ul> <li>Tablets may be crushed (10, 20, and 40 mg)</li> <li>Flavored powder for suspension (40 mg/5 mL)</li> <li>Intravenous formulation available<sup>¥</sup></li> <li>Chewable tablets (10 mg, with antacid [calcium carbonate-magnesium hydroxide antacid])</li> </ul> </td> </tr> <tr> <td class="indent1">Nizatidine</td> <td>Children: <ul class="decimal_heading"> <li>10 mg/kg/day divided into 2 doses<sup>§</sup></li> </ul> <p class="extra_spacing_top">Adults:</p> <ul class="decimal_heading"> <li>150 mg/dose twice daily or 300 mg once daily at bedtime</li> </ul> </td> <td> <ul> <li>Similar to cimetidine, except that nizatidine <strong>lacks</strong> anti-androgenic activity (gynecomastia) and does <strong>not</strong> inhibit CYP metabolism or alter co-administered drugs metabolized by CYP<sup>*</sup>.</li> <li>Low levels of NDMA contaminants have been found in some nizatidine products<sup>†</sup>.</li> </ul> </td> <td> <ul> <li>Oral tablets may be crushed (150 and 300 mg)</li> <li>Flavored oral solution (15 mg/mL)</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Prokinetics<sup>‡</sup></td> </tr> <tr> <td class="indent1">Cisapride<sup>**</sup></td> <td>Children: <ul class="decimal_heading"> <li>0.6 to 0.8 mg/kg per day, divided into 4 doses, given 30 minutes before each meal and at bedtime</li> <li>Maximum 10 mg per dose</li> </ul> <p class="extra_spacing_top">Adults:</p> <ul class="decimal_heading"> <li>5 to 20 mg 4 times daily</li> </ul> </td> <td> <ul> <li>Cisapride is not available in the United States. The only way that United States clinicians can obtain cisapride is through a limited-access program developed by Janssen Pharmaceuticals and the United States FDA<sup>**</sup>.</li> <li><strong>Frequent:</strong> <ul> <li>Abdominal pain, diarrhea, headache, dizziness.</li> </ul> </li> <li><strong>Infrequent or rare:</strong> <ul> <li><strong>NOTE –</strong> Cisapride may increase the risk for <strong>potentially fatal ventricular arrhythmias</strong> due to QT prolongation.</li> <li><strong>NOTE –</strong> If prescribed, requires assessment of risk factors for cardiac arrhythmias, including ECG and serum electrolytes<sup>¶¶</sup> and close attention to avoiding co-administration of drugs that can elevate cisapride blood levels and/or also prolong the QT interval, including macrolide antibiotics, azole antifungals, and protease inhibitors. For specific interactions, refer to the <a href="https://www.uptodate.com/drug-interactions">drug interactions program</a> included with UpToDate.</li> <li>Hypersensitivity reactions (rash, bronchospasm), convulsions, dystonic reactions (mostly adult reports).</li> </ul> </li> </ul> </td> <td> <ul> <li>Restricted availability in the United States<sup>**</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p><em>C. difficile</em>: <em>Clostridioides</em> (formerly <em>Clostridium</em>) <em>difficile</em>; CNS: central nervous system; CYP: cytochrome P450; ECG: electrocardiogram; FDA: Food and Drug Administration; GERD: gastroesophageal reflux disease; H2RA: histamine<sub>2</sub> receptor antagonist; NDMA: n-nitrosodimethylamine; NG: nasogastric; PPI: proton pump inhibitor; SSRI: selective serotonin reuptake inhibitor.</p>
<p>* For additional information about adverse effects, refer to separate UpToDate topic reviews of proton pump inhibitors in the treatment of acid-related disorders and the pharmacology of antiulcer medications. Additional information is available in the Lexicomp individual drug topics.</p>
<p>¶ Preparations shown in the table are those available in the United States and some other countries.</p>
<p>Δ Acid suppression with PPIs or H2RAs may be a risk factor for lower respiratory tract infections, particularly in infants and young children.</p>
<p>◊ Relative potency varies among PPIs. Bioequivalent doses for acid suppression are pantoprazole 0.23, lansoprazole 0.9, omeprazole 1.0, esomeprazole 1.6, and rabeprazole 1.8<sup>[4]</sup>.</p>
<p>§ In general, the pediatric dose should not exceed the higher end of the adult dose. On a milligram per kilogram basis, doses of some of the PPIs needed to obtain a similar degree of acid suppression in children are greater than those for adolescents and adults. Optimally, PPIs are given once daily approximately 30 minutes before the first meal of the day, or if given twice daily, prior to the first meal and the evening meal.</p>
<p>¥ Intravenous formulations are available for some PPIs and H2RAs and may be used when oral therapy is inappropriate or not possible (eg, patients in intensive care for stress ulcer prophylaxis). Further information on intravenous preparations and dosing is available in the Lexicomp individual drug topics.</p>
<p>‡ Dose adjustment of H2RAs is needed in the setting of kidney function impairment.</p>
<p>† Ranitidine (an H2RA) was withdrawn from the market in the United States in April 2020 due to concerns about contamination of some ranitidine products with N-Nitrosodimethylamine (NDMA), a probable human carcinogen<sup>[5]</sup>. The NDMA concentrations increase over time, especially when stored at higher than room temperatures.</p>
<p>** In the United States, prescriptions for cisapride can only be filled through an investigational limited-access program from the manufacturer, after providing documentation of the need for cisapride and assessment of risk factors for cardiac arrhythmias in the individual patient (eg, a QTc &gt;450 ms). Cisapride is available in several other countries. Refer to UpToDate topic on acquired long QT syndrome for details.</p>
¶¶ Systematic reviews have not supported the use of metoclopramide, cisapride, erythromycin, or domperidone for treatment of GERD. These drugs should be considered for use only in carefully selected patients who have delayed gastric emptying because of gastric dysmotility (gastroparesis), contributing to GERD. Refer to the UpToDate topic on treatment of gastroparesis.</div><div class="graphic_reference">Data from:
<ol>
<li>Lightdale JR, Gremse DA and the section on Gastroenterology, Hepatology and Nutrition. Gastroesophageal reflux: Management guidance for the pediatrician. Pediatrics 2013; 131:e1684.</li>
<li>Vandenplas Y, Rudolph D, et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49:498.</li>
<li>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2018.</li>
<li>Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65:19.</li>
<li>FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. U.S. Food &amp; Drug Administration. Available at: <a href="https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market" target="_blank">https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market</a> (Accessed on April 7, 2020).</li>
</ol></div><div id="graphicVersion">Graphic 55435 Version 25.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
